BioWorld

June 22, 2004

View Archived Issues

Titan Halts Phase II Studies Of Pivanex In NSCL Cancer

Safety concerns prompted Titan Pharmaceuticals Inc. to stop a year-old Phase IIb study of its cancer drug Pivanex. (BioWorld Today) Read More

Neurochem Enters Phase III Alzhemed Alzheimer's Trial

Read More

As BioShield Signing Nears, BioShield II Planning Begins

Read More

Tercica Plans NDA Filing After Positive Phase III rhIGF-1 Data

Read More

Other News To Note

Read More

Appointments And Advancements

Read More